BACKGROUND: The standard treatment of advanced melanoma has been changing in 
recent years. Palliative chemotherapy is being replaced by more efficient 
targeted therapies and modern immunotherapies based on antibodies against 
checkpoints of the immune response (so  called checkpoint inhibitors). Todays 
standard ipilimumab (ant-iCTLA 4 antibody) could significantly prolong overall 
survival and achieved longterm disease control in about 20% of patients. There 
are other perspective immune modulating agents, such as anti-PD 1 antibodies 
(nivolumab, pembrolizumab, pidilizumab) and anti-PD L1 antibodies. Unique 
mechanism of action is accompanied by new types of immunerelated adverse events.
AIM: The aim of the article is to summarize current knowledge about the toxicity 
of these antibodies and propose solutions in routine clinical practice.